



Melissa L Johnson

Kontakt

Melissa L Johnson

Publikationen (2)

Johnson M, Rich P, Hung J, Appenzeller C, Sun Z, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, van der Leest C, Okamoto I, Zvirbule Z, Laktionov K, Helland A, Cho B, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Bar J. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study. *J Thorac Oncol* 2021; 16:1570-1581.

Peters S, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd F, Kurata T, Li Z, Qiu J, Kowanetz M, Mucci S, Shankar G, Sandler A, Früh M, Ho C, Gettinger S, Johnson M, Jänne P, Garassino M, Christoph D, Toh C, Rizvi N, Chafit J, Carcereny Costa E, Patel J, Chow L, Koczywas M, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). *J Clin Oncol* 2017; 35:2781-2789.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch